Lineage Point Capital LP Purchases Shares of 232,642 Oaktree Acquisition Corp. III Life Sciences $OACC

Lineage Point Capital LP purchased a new stake in shares of Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 232,642 shares of the company’s stock, valued at approximately $2,461,000.

Several other hedge funds and other institutional investors also recently modified their holdings of OACC. Empyrean Capital Partners LP increased its position in shares of Oaktree Acquisition Corp. III Life Sciences by 20.0% in the fourth quarter. Empyrean Capital Partners LP now owns 900,000 shares of the company’s stock worth $9,522,000 after purchasing an additional 150,000 shares during the last quarter. Radcliffe Capital Management L.P. lifted its position in Oaktree Acquisition Corp. III Life Sciences by 67.1% during the fourth quarter. Radcliffe Capital Management L.P. now owns 377,065 shares of the company’s stock valued at $3,989,000 after purchasing an additional 151,403 shares during the last quarter. Sculptor Capital LP lifted its position in Oaktree Acquisition Corp. III Life Sciences by 6.1% during the fourth quarter. Sculptor Capital LP now owns 530,537 shares of the company’s stock valued at $5,613,000 after purchasing an additional 30,537 shares during the last quarter. Verition Fund Management LLC lifted its position in Oaktree Acquisition Corp. III Life Sciences by 91.5% during the fourth quarter. Verition Fund Management LLC now owns 309,740 shares of the company’s stock valued at $3,293,000 after purchasing an additional 148,000 shares during the last quarter. Finally, Meteora Capital LLC grew its stake in Oaktree Acquisition Corp. III Life Sciences by 402.0% in the 3rd quarter. Meteora Capital LLC now owns 248,500 shares of the company’s stock worth $2,612,000 after buying an additional 199,000 shares in the last quarter.

Oaktree Acquisition Corp. III Life Sciences Price Performance

OACC stock opened at $10.67 on Friday. The company’s 50 day moving average price is $10.68 and its two-hundred day moving average price is $10.65. Oaktree Acquisition Corp. III Life Sciences has a one year low of $10.30 and a one year high of $10.74.

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) last posted its quarterly earnings results on Thursday, March 26th. The company reported $0.08 earnings per share (EPS) for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Oaktree Acquisition Corp. III Life Sciences in a report on Thursday, April 2nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Oaktree Acquisition Corp. III Life Sciences presently has a consensus rating of “Sell”.

Oaktree Acquisition Corp. III Life Sciences Company Profile

Oaktree Acquisition Corp. III Life Sciences (NASDAQ: OACC) is a special purpose acquisition company (“SPAC”) formed to pursue merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combinations with one or more businesses in the life sciences sector. Incorporated as a Cayman Islands exempted company, OACC is sponsored by Oaktree Capital Management, a global alternative investment firm with a longstanding track record in credit strategies and private equity.